|
| Management Team |
Neal Fowler, Chief Executive Officer
Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Neal served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company's legacy of double-digit growth for their flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler was president of Ortho-McNeil Neurologics Inc. and vice president of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company, where he doubled sales of the cardiovascular business unit over a three-year period. Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill (UNC-CH).
|
Bruce Boucher, Chief Financial Officer
Mr. Boucher joined Liquidia in 2004 and is currently Chief Financial Officer. Prior to joining Liquidia, Mr. Boucher was General Manager and Chief Financial Officer for Magellan Laboratories; an entrepreneurial, high-growth business headquartered in Research Triangle Park, NC, which ultimately sold to Cardinal Health in 2002. Mr. Boucher was previously involved with the expansion of the ClinTrials Research business in various corporate and operational rolls that provided clinical trial testing and data services to the pharmaceutical industry. Mr. Boucher was also a practice manager with Price Waterhouse in areas of audit, business valuations, transaction support and international tax servicing high tech, petrochemical and financial services organizations.
|
Kyle Chenet, Vice President, Corporate Development
Mr. Chenet joined Liquidia in 2007 from Biolex Therapeutics where he was focused on executing new partnerships with pharmaceutical companies intent on leveraging Biolex' protein engineering and production technology to enable new therapeutic protein products. Prior to joining Biolex, Mr. Chenet was a Director in GlaxoSmithKline's Worldwide Business Development where he was responsible for evaluating and negotiating worldwide licensing agreements across multiple therapeutics areas. Prior to GSK, Mr. Chenet spent several years as a manager at Abbott Laboratories. Mr. Chenet has a M.B.A. from Stanford University and a B.S.E from the University of Michigan.
|
Frank J. Malinoski, M.D., Ph.D., Chief Medical Officer
Dr. Malinoski has more than 20 years of executive experience in the biotech and pharmaceutical industries, including work in clinical and global business development, regulatory evaluation, and post-approval oversight for numerous vaccines and immunotherapy products. Dr. Malinoski has extensive background in the fields of vaccines, immunology, oncology, infectious disease and other key therapeutic areas. Prior to joining Liquidia in 2010, Dr. Malinoski held senior positions in clinical research, business development, and medical affairs at Wyeth, MedImmune, Nabi and several other biopharmaceutical companies. His responsibilities included pre-licensure clinical evaluation and post-licensure activities in support of vaccines and immunotherapy, and his efforts contributed to the licensure of Prevnar, Meningitec, and Tetramune vaccines. Dr. Malinoski received his B.A. from Colby College, his M.D. from Albany Medical College, and his Ph.D. in microbiology from Rutgers University.
|
Jonathan Smith, Ph.D., Chief Scientific Officer
Dr. Smith is a pioneer in the development of novel vaccines based on RNA viruses and has over twenty five years of experience in virology, infectious diseases, and vaccine development. Prior to joining Liquidia, Dr. Smith was a co-founder and served as Chief Scientific Officer of AlphaVax, a biotechnology company focused on developing vaccines for infectious disease and cancer. At AlphaVax, Dr. Smith was responsible for optimizing vaccine vector technologies, developing clinical and regulatory strategies, and generating vaccine candidates and adjuvants based on vector technologies. His efforts resulted in over 20 issued patents and contributed to the advancement of multiple vaccine candidates into clinical studies. Prior to Alphavax, Dr. Smith was a faculty member in the Department of Microbiology at the University of Maryland Medical School (UMAB), and Chief of Viral Biology at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Dr. Smith received his B.A. from Colby College and his Ph.D. in microbiology/virology from the University of Texas at Austin. He conducted post doctoral research at the Institute for Genetics in Cologne, Germany, and has co-authored over 90 publications in leading journals.
|
Joseph DeSimone, Ph.D. Founder & Scientific Advisor
Professor DeSimone founded Liquidia Technologies in 2004 with his colleagues at The University of North Carolina at Chapel Hill (UNC). Dr. DeSimone holds distinguished faculty positions at UNC and North Carolina State University, and has co-founded multiple companies including Bioabsorbable Vascular Solutions, which was acquired in 2003 by Guidant Corporation. In 2005 Dr. DeSimone was elected into the National Academy of Engineering and the American Academy of Arts and Sciences. He is the recipient of numerous awards and recognitions including the prestigious 2008 Lemelson-MIT Prize for inventors and the 2009 NIH Director’s Pioneer Award. Dr. DeSimone is credited with over 100 issued patents and more than 250 published articles. He received his BS in Chemistry from Ursinus College and his Ph.D. in Chemistry from Virginia Tech. |
|
|
|
